The state of California currently has 207 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Study Assessing QBS72S For Treating Brain Metastases
NCT05305365
Recruiting
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic breast cancer with CNS involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Stanford Cancer Institute, Palo Alto, California
Conditions: Brain Metastases, Breast Cancer
Register for Updates
A Culturally Sensitive Social Support Intervention
NCT02946697
Recruiting
This study is a randomized controlled trial (RCT) to assess the impact of a culturally based social support program (i.e. Joy Luck Academy, JLA) among Chinese American breast cancer survivors.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Herald Cancer Association, Los Angeles, California
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT04768426
Recruiting
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical tria... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Stanford University, Stanford, California
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: City of Hope, Duarte, California
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT05376878
Recruiting
This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography [PET]/magnetic resonance imaging [MRI]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Register for Updates
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574
Recruiting
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: NGM Clinical Study Site, Los Angeles, California
Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Register for Updates
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044
Recruiting
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovaria... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California +1 locations
Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Register for Updates
A Multicenter Cancer Biospecimen Collection Study
NCT04510129
Recruiting
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Curebase, San Francisco, California
Conditions: Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Register for Updates
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT05298605
Recruiting
The purpose of this research is to develop a culturally adapted "Faith in Action!" curriculum to train lay health navigators to provide breast cancer screening navigation to Korean American women within faith-based settings and evaluate whether the culturally adapted "Faith in Action!" curriculum increases adherence to breast cancer screening guidelines among Korean American women within faith-based settings in Los Angeles, California. The primary research procedures include trainings and key in... Read More
Gender:
Female
Ages:
Between 45 years and 80 years
Trial Updated:
02/05/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Conditions: Breast Cancer Female, Health Knowledge, Attitudes, Practice, Cancer Screening, Health Disparities
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: City of Hope - Duarte, Duarte, California +6 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
NCT03696030
Recruiting
This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent). HER2-CAR T cells delivered into the ventricles of the brain may recognize and kill tumor cells.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT04821141
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
Female
Ages:
Between 45 years and 64 years
Trial Updated:
01/25/2024
Locations: City of Hope Medical Center, Duarte, California +1 locations
Conditions: Risk Reduction, Breast Cancer
Register for Updates